GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Administration of GV1001 1.12 mg/Day in Patients With Moderate to Severe Alzheimer Disease

The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).

Study Overview

• Status: Not yet recruiting
• Conditions: Moderate to Severe Alzheimer's Disease
• Intervention / Treatment: Drug: GV1001 Placebo; Drug: GV1001 1.12mg

Detailed Description

Studies using in vivo and in vitro Alzheimer's Disease (AD) models have shown that GV1001 inhibits neurotoxicity, apoptosis, and the production of reactive oxygen species induced by amyloid beta (Aβ) in neural stem cells by mimicking the extra-telomeric functions of human telomerase reverse transcriptase (hTERT). In nonclinical studies, using both mild (early stage) and severe (late stage) AD mouse models, GV1001 was shown to improve cognitive function and memory, as well as significantly reduce the amount of Aβ and tau proteins. The multifunctional effect of GV1001 makes it a promising therapeutic option for the treatment for AD. In a completed Phase 2 study (NCT03184467) conducted in Korea, GV1001 showed significant improvement in change from baseline of Severe Impairment Battery score at Week 24 and demonstrated a clinically acceptable safety profile in patients with moderate to severe AD.

This is a multi-center, randomized, double-blinded, placebo-controlled, parallel design, prospective phase 3 study in participants with moderate to severe AD. The study consists of 24 weeks of Double-blind phase and 25 weeks of open-label phase.

• Study Type: Interventional
• Enrollment (Estimated): 750
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Kyounghee Seo; Phone Number: +82 31 353 6681; Email: khseo@sspharm.co.kr
• Study Contact Backup: Name: Soyoung Park; Phone Number: +82 70 4840 9243; Email: soyoung@sspharm.co.kr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subjects aged ≥ 55 to ≤ 85 years
2. Subjects who satisfy diagnostic criteria for dementia in DSM-IV (Diagnostic and Statistical Manual of Mental Disorders Fourth edition)
3. Subjects who are clinically diagnosed with probable Alzheimer's disease as defined in the NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association) criteria
4. Subjects with a K-MMSE (Korea Mini-Mental State Examination) score ≤ 19 at the screening visit
5. Subjects with GDS (Global Deterioration Scale) grade 5 to 6
6. Subjects who have no other diseases to cause dementia other than AD as a result of MRI or CT scan within 12 months from the screening visit
7. Subjects who are taking donepezil alone or donepezil and memantine in combination at a stable dose without a dose change over 3 months before screening
8. Subjects who are not illiterate
9. Subjects who can walk with or without assist device to visit hospitals or clinics to undergo cognitive tests and other tests
10. Subjects with caregiver who can accompany all visits with the subjects as scheduled for this trial, supervise subject's compliance for the tests and examination process and provide information about the subject's indications, and who give written consent
11. Subjects and/or legal representative who voluntarily agreed in written to participate in the clinical trial

Exclusion Criteria:

1. Subjects who have other causes of dementia as listed below according to CT/MRI test and neurologic examination within 12 months of screening or at the time of screening.

   • Subjects with possible, probable or definite vascular dementia according to NINDS-AIREN (National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences) criteria
   • Subjects with other central nervous system diseases that can cause the impairment of cognitive function (cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease, etc.)
   • Subjects with neuropathy such as delusion, delirium, epilepsy, etc.
2. Subjects who have abnormal test results which are considered to contribute to the severity of their dementia or be the cause of dementia in the vitamin B12, folic acid, syphilis serology, and the thyroid stimulating hormone (TSH) tests
3. Subjects who have a history of significant psychiatric illness such as schizophrenia or bipolar affective disorders which may interfere with the participation of this clinical trial according to the investigator's judgment or who are suffering from depression
4. Subjects with a history of known or suspected seizures including febrile seizure, recent loss of consciousness which is not explained or history of significant head trauma accompanied by loss of consciousness
5. Subjects in any medical condition that may interfere with the evaluation and progression of the clinical trial according to the investigator's judgment (acute or unstable cardiovascular disease, uncontrolled hypertension (>160/100 mmHg) at Visit 1 and Visit 2, insulin-dependent or uncontrolled diabetes at Visit 1 (HbA1c> 8% on screening test), etc.).
6. Subjects who are hypersensitive to the components of the investigational product.
7. Subjects with a history of alcohol and drug abuse or dependence (except nicotine dependence) within the last 2 years.
8. Subjects with a history of cancer within the past 5 years (however, non-metastatic skin basal cell carcinoma and/or skin squamous cell carcinoma, carcinoma in suit of uterine cervix or non-progressive prostate cancer may be acceptable and If cancer is considered to have been treated at the judgement of the investigator, if subjects are not taking anticancer or radiation therapy and are considered that treatment is not required for the next 5 years at the discretion of the investigator, enrollment is possible)
9. Subjects with renal dysfunction (Creatinine Clearance (Clcr) < 30 mL/min)
10. Subjects with serious hepatic dysfunction (Alanine aminotransferase or Aspartate aminotransferase ≥ 2.0 normal upper limit)

11. Subjects currently receiving or expected to receive medications prohibited in this clinical trial during the trial period

    • Donepezil, memantine, or other medications for the treatment of Alzheimer's disease (acetylcholinesterase inhibitors (rivastigmine, galantamine), anti-amyloid antibodies (lecanemab, donanemab), etc.) or other medications for the treatment of cognitive impairment.

12. Subjects with previous administration of all clinical trial vaccines for Alzheimer's disease

13. Among subjects who consented to lumbar puncture (LP) for cerebrospinal fluid (CSF) collection, patients meeting the following criteria

    - Patients with contraindications for lumbar puncture (e.g., platelet count <100,000/μL, lumbar deformity, etc.) (However, even if a subject has contraindications for lumbar puncture, they may still participate in this clinical trial.)

14. Female subjects with childbearing potential who do not agree to contraception using a medically accepted method (complete celibacy; hormonal contraceptives: Levonorgestrel, Intrauterine system of Mirena, and Medroxyprogesterone; and surgical sterilizations: vasectomy, double tubectomy, double tubal ligation) during the clinical trial period and until 90 days after clinical trial end (stop).
15. Pregnant or lactating women
16. Subjects who participated in another clinical trial within 4 weeks before participation in this clinical trial
17. Subjects in less than 12 months after the administration of the Investigational product for this clinical trial
18. Subjects who participated in any clinical trial for Alzheimer type dementia treatment within 6 months at screening
19. Subjects who are judged by the investigator to be ineligible for participation in this clinical trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: GV1001 Placebo; GV1001 placebo (0.9% saline) subcutaneous injection will be administered once a week for 4 weeks and then administered every 2 weeks for 20 weeks in a double-blind phase. During the open-label extension phase, patients assigned to the GV1001 Placebo arm in the double-blind phase will receive a placebo in the first week, followed by 1.12 mg of GV1001 weekly for 4 weeks and then every 2 weeks until EOT (End of Treatment).	Drug: GV1001 Placebo; 0.9% normal saline; Other Names: Normal saline; Drug: GV1001 1.12mg; Lyophilized peptide from hTERT; Other Names: Tertomotide 1.68mg
Experimental: GV1001 1.12 mg; GV1001 1.12 mg subcutaneous injection will be administered once a week for 4 weeks and then administered every 2 weeks for 20 weeks in a double blind phase. During the open-label extension phase, patients will alternate between 1.12 mg of GV1001 and placebo weekly for the first 5 weeks to maintain double blindness, and then 1.12mg of GV1001 every 2 weeks until EOT.	Drug: GV1001 Placebo; 0.9% normal saline; Other Names: Normal saline; Drug: GV1001 1.12mg; Lyophilized peptide from hTERT; Other Names: Tertomotide 1.68mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in SIB(Severe Impairment Battery) score after GV1001 administration for 24 weeks	SIB includes 51 questions to assess cognition in an individual. SIB consists of nine symptom domains such as attention, language, orientation, memory, praxis, visuospatial perception, construction, social skills and orientating head to name. The possible total scores range from 0 to 100 with a higher score indicating greater cognitive function.	Baseline, Week 26
CIBIC-plus (Clinician Interview-Based Impression of Change-Plus) score after GV1001 administration for 24 weeks	CIBIC-plus consists of 4 items: "Overall," "Mental and Cognitive Function," "Behavior," and "Daily Function." CIBIS, a 7-point severity assessment, is administered at baseline. CIBIC-plus is implemented at follow-up visits to evaluate the degree of change in overall functional status in 7 levels by referring to the CIBIS results evaluated at baseline. The overall clinical condition of the dementia patient is assessed based on information obtained from semi-structured interviews of patients and caregivers. The rater is independent, has clinical experience, and will evaluate the subjects after completing the training required for this study.	Baseline, Week 26

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in SIB(Severe Impairment Battery) score	SIB includes 51 questions to assess cognition in an individual. SIB consists of nine symptom domains such as attention, language, orientation, memory, praxis, visuospatial perception, construction, social skills and orientating head to name. The possible total scores range from 0 to 100 with a higher score indicating greater cognitive function.	Baseline, Week 6, and Week 14
CIBIC-plus (Clinician Interview-Based Impression of Change-Plus) score after GV1001 administration	CIBIC-plus consists of 4 items: "Overall," "Mental and Cognitive Function," "Behavior," and "Daily Function." CIBIS, a 7-point severity assessment, is administered at baseline. And CIBIC-plus is implemented at follow-up visits to evaluate the degree of change in overall functional status in 7 levels by referring to the CIBIS results evaluated at baseline. The overall clinical condition of the dementia patient is assessed based on information obtained from semi-structured interviews of patients and caregivers. The rater is independent, has clinical experience, and will evaluate the subjects after completing the training required for this study.	Baseline, Week 6, and Week 14
Change from baseline in K-MMSE(Korea Mini-Mental State Examination) score after GV1001 administration	K-MMSE assesses an individual's cognitive function by asking questions about time orientation, spatial orientation, memory registration, attention and calculation, memory recall, language, and space-time configuration. It creates the possible total score from 0 to 30, with a lower total score indicating greater severity in cognitive impairment.	Baseline, Week 6 week, Week 14, and Week 26
Change from baseline in NPI-Q(Neuropsychiatric Inventory Questionnaire) score after GV1001 administration	NPI-Q consists of questions to evaluate degrees of behavioral disturbance in 12 domains. It includes delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, and appetite/eating. The severity scale has scores ranging from 1 to 3 points (1=mild and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress and 5=extreme distress). The higher sum of the NPI-Q severity score represents greater severity of the individual's symptoms, and the higher sum of the NPI-Q distress score indicates greater severity of caregiver's distress associated with the symptoms.	Baseline, Week 6 week, Week 14, and Week 26
Change from baseline in GDS(Global Deterioration Scale) score after GV1001 administration	GDS provides the stages for the severity of cognitive function of the individual with AD. It is brown down into seven stages (stage1=no cognitive decline and 7=very severe cognitive decline).	Baseline, Week 6 week, Week 14, and Week 26
Change from baseline in ADCS-ADL-severe(Alzheimer's Disease Cooperative Study-Activities of Daily Living scale-severe) score after GV1001 administration	ADCS-ADL-severe consists of 19 items that can access the competence of individuals with AD in activities of daily living. The maximum possible total score is 54, with a higher score indicating lesser severity in AD.	Baseline, Week 6 week, Week 14, and Week 26
Change from baseline in CDR-SOB(Clinical Dementia Rating Scale Sum of Boxes) score after GV1001 administration	CDR-SOB evaluates cognitive and functional performance in six domains related to AD including memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated from 0 to 5 points (0, 0.5, 1, 2, 3, 4, and 5) with a lower total score indicating severely impaired cognitive function.	Baseline, Week 6 week, Week 14, and Week 26

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory Assessment	[Biomarker Test] - Plasma: Change from baseline (Visit 1) to Week 24 and Week 48 of Investigational Product (IP) administration in Amyloid Beta Peptide 1-42 (Aβ1-42), Aβ1-40, total Tau (t-Tau), phosphorylated Tau (p-Tau), p-Tau 181, p-Tau 217, p-Tau 231, Neurofilament Light Chain (NfL), Glial Fibrillary Acidic Protein (GFAP) change / Unit of Measure: pg/mL	Change from baseline to Week 24 and Week 48 of IP administration
Exploratory Assessment	[Biomarker Test] - Cerebrospinal Fluid (CSF): Change from baseline (Visit 2) to Week 24 and Week 48 of Investigational Product (IP) administration in Aβ1-42, Aβ1-40, t-Tau, p-Tau, p-Tau 181, p-Tau 217, p-Tau 231, NfL, GFAP, Brain-Derived Neurotrophic Factor (BDNF), YKL-40, Neurogranin, Neuron-Specific Enolase (NSE), S100B change / Unit of Measure: pg/mL or ng/mL	Change from baseline to Week 24 and and Week 48 of IP administration
Exploratory Assessment	[Long-term administration] Change in Severe Impairment Battery (SIB) score at 28, 36, and 48 weeks after administration of the investigational drug compared to baseline /Unit of Measure: Severe Impairment Battery (SIB) scale (values range from 0 to 100; higher scores indicate a better outcome / less cognitive impairment)	28, 36, and 48 weeks after administration of IP
Exploratory Assessment	[Long-term administration] Change in Clinical Dementia Rating-Sum of Boxes (CDR-SOB) score at 28, 36, and 48 weeks after administration of the investigational drug compared to baseline / Unit of Measure: Clinical Dementia Rating-Sum of Boxes (CDR-SOB) scale (total scores range from 0 to 18; higher scores indicate a worse outcome / greater cognitive and functional impairment)	28, 36, and 48 weeks after administration of IP
Exploratory Assessment	[Long-term administration] Change in Korean Mini-Mental State Examination (K-MMSE) score at 28, 36, and 48 weeks after administration of the investigational drug compared to baseline / Unit of Measure: Korean Mini-Mental State Examination (K-MMSE) scale (values range from 0 to 30; higher scores indicate a better outcome / better cognitive function)	28, 36, and 48 weeks after administration of IP
Exploratory Assessment	[Long-term administration] Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living - Severe (ADCS-ADL-severe) score at 28, 36, and 48 weeks after administration of the investigational drug compared to baseline / Unit of Measure: Alzheimer's Disease Cooperative Study - Activities of Daily Living - Severe (ADCS-ADL-severe) scale (values range from 0 to 18; higher scores indicate a better outcome / better functional ability)	28, 36, and 48 weeks after administration of IP
Exploratory Assessment	[Long-term administration] Change in Global Deterioration Scale (GDS) score at 28, 36, and 48 weeks after administration of the investigational drug compared to baseline / Unit of Measure: Global Deterioration Scale (GDS) (stages range from 1 to 7; higher scores indicate a worse outcome / greater cognitive decline)	28, 36, and 48 weeks after administration of IP
Exploratory Assessment	[Long-term administration] Change in Neuropsychiatric Inventory Questionnaire (NPI-Q) score at 28, 36, and 48 weeks after administration of the investigational drug compared to baseline / Unit of Measure: Neuropsychiatric Inventory Questionnaire (NPI-Q) scale (total severity scores range from 0 to 36; higher scores indicate a worse outcome / more severe neuropsychiatric symptoms)	28, 36, and 48 weeks after administration of IP
Exploratory Assessment	[Long-term administration] Change in Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) score at 28, 36, and 48 weeks after administration of the investigational drug compared to baseline / Unit of Measure: Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) scale (values range from 1 to 7; higher scores indicate a worse outcome / clinical worsening)	28, 36, and 48 weeks after administration of IP

Collaborators and Investigators

• Sponsor: Samsung Pharmaceutical Co., Ltd.
• Investigators: Study Director: Kyounghee Seo, Samsung Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2027
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): July 1, 2031

Study Registration Dates

• First Submitted: March 15, 2022
• First Submitted That Met QC Criteria: March 28, 2022
• First Posted (Actual): March 31, 2022

Study Record Updates

• Last Update Posted (Actual): June 10, 2026
• Last Update Submitted That Met QC Criteria: June 8, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Alzheimer's Disease; GV1001
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Mental Disorders; Neurocognitive Disorders; Dementia; Tauopathies; Neurodegenerative Diseases; Alzheimer Disease; Pharmaceutical Preparations; Crystalloid Solutions; Isotonic Solutions; Solutions; Saline Solution
• Other Study ID Numbers: GV1001-AD-CL3-S002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No